KUALA LUMPUR: Bintai Kinden Corporation Bhd’s partner Generex Biotechnology Corporation has filed for a trademark for its li-Key vaccine and patent for its Ii-Key-SARS-CoV-2 vaccine.
In a statement issued on Thursday, Bintai Kinden said the Ii-Key vaccine was designed to be a complete vaccine for the Covid-19.
“The technology offers the safest and best route for the rapid development of a Covid-19 vaccine, ” it said.
It explained the complete vaccine is designed to regulate the immune system to provide a targeted, neutralising antibody response.
Bintai Kinden managing director Ong Choon Lui said Generex’s Covid-19 vaccine was based on the results of the ex-vivo human studies. It will be formulated for phases one and two clinical trials.
The statement also said Generex’s subsidiary NuGenerex Immuno-Oncology Inc is exploring opportunities to deploy the targeted Covid-19 vaccine as a universal booster for RNA, DNA, and inactivated virus vaccines that contain the entire spike protein and have the potential to elicit off-target and over-active immune responses.
Bintai Healthcare Sdn Bhd was granted the exclusive rights from Generex and NuGenerex to distribute, sell and commercialize the Covid-19 vaccine in Malaysia, Brunei, Myanmar, Cambodia, Timor-Leste, Indonesia, Laos, the Philippines, Singapore, Thailand and Vietnam.
It has also been given the first right of refusal to distribute and market the vaccine within Australia, New Zealand and the global halal market.
Did you find this article insightful?
78% readers found this article insightful